Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Nuoncology Labs stock price, quote, forecast and news

NLAB
US67057T1079
916415

Price

0
Today +/-
-0
Today %
-0 %
P

Nuoncology Labs stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Nuoncology Labs stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Nuoncology Labs stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Nuoncology Labs stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Nuoncology Labs's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Nuoncology Labs Stock Price History

DateNuoncology Labs Price
7/1/20220 undefined
6/30/20220 undefined

Nuoncology Labs Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Nuoncology Labs, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Nuoncology Labs from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Nuoncology Labs’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Nuoncology Labs. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Nuoncology Labs’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Nuoncology Labs’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Nuoncology Labs’s growth potential.

Nuoncology Labs Revenue, EBIT and net profit per share

DateNuoncology Labs RevenueNuoncology Labs EBITNuoncology Labs Net Income
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
19980 undefined0 undefined0 undefined

Nuoncology Labs Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
1998201920202021
0000
----
----
0000
0000
----
0000
----
9.4598.2898.3898.38
----
Details

Keystats

ⓘ

Revenue and Growth

The Nuoncology Labs Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Nuoncology Labs is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (k)RECEIVABLES (k)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (k)CURRENT ASSETS (k)TANGIBLE ASSETS (k)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (k)PROVISIONS (k)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (k)LONG-T. LIAB. (k)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (k)DEBT (k)TOTAL CAPITAL (M)
1998201920202021
       
115000
12000
0000
0000
60000
187000
210000
5.4000
0000
0000
4.44000
155000
10.21000
10.39000
       
189.839.8310.38
10.9210.8110.8110.84
-0.6-10.82-10.82-10.85
-0.23000
0000
10.11-0-00
247000
10000
9000
0000
4000
270000
20000
0000
0000
20000
290000
10.4-0-00
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Nuoncology Labs provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Nuoncology Labs's financial health and stability.

Assets

Nuoncology Labs's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Nuoncology Labs must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Nuoncology Labs after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Nuoncology Labs's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (k)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
199820202021
000
000
000
000
000
000
000
000
000
000
000
000
000
1,00000
000
---
000
000
000
000

Nuoncology Labs stock margins

The Nuoncology Labs margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Nuoncology Labs. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Nuoncology Labs.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Nuoncology Labs's sales revenue. A higher gross margin percentage indicates that the Nuoncology Labs retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Nuoncology Labs's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Nuoncology Labs's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Nuoncology Labs's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Nuoncology Labs. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Nuoncology Labs's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Nuoncology Labs Margin History

Nuoncology Labs Gross marginNuoncology Labs Profit marginNuoncology Labs EBIT marginNuoncology Labs Profit margin
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
19980 %0 %0 %

Nuoncology Labs Stock Sales Revenue, EBIT, Earnings per Share

The Nuoncology Labs earnings per share therefore indicates how much revenue Nuoncology Labs has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Nuoncology Labs earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Nuoncology Labs's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Nuoncology Labs’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Nuoncology Labs's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Nuoncology Labs Revenue, EBIT and net profit per share

DateNuoncology Labs Sales per ShareNuoncology Labs EBIT per shareNuoncology Labs Earnings per Share
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
19980 undefined0 undefined0 undefined

Nuoncology Labs business model

Nuoncology Labs Inc is a biotechnology company specialized in the development of novel cancer therapies. It was founded in 2015 by experienced scientists and entrepreneurs in the field of biotechnology. The main goal of Nuoncology Labs Inc is to develop better and more effective treatments for cancer. The company relies on innovative technologies and approaches to specifically target and combat cancer cells without damaging healthy tissue. An essential element of Nuoncology Labs Inc's business model is its close collaboration with leading research institutions worldwide. Through these partnerships, the company is able to access the latest knowledge and technologies in cancer research and utilize them for its own development of therapy approaches. Nuoncology Labs Inc is divided into various divisions, each focusing on specific aspects of cancer research and treatment. One important division is the exploration of novel drug candidates that target specific types and stages of cancer. The company utilizes state-of-the-art drug screening technology to identify and optimize promising candidates. Another division of Nuoncology Labs Inc focuses on the development of innovative diagnostic tools for cancer early detection and diagnosis. These tools incorporate advanced technologies such as liquid biopsy and imaging techniques to detect tumor cells and DNA alterations in the blood. Furthermore, a central focus of Nuoncology Labs Inc is the development of targeted therapies that aim at specific signaling pathways in cancer cells. The company utilizes antibodies and other targeted agents that target specific receptors or proteins in the cancer cells. An additional important product of Nuoncology Labs Inc is an innovative therapy system for immuno-oncology. This method aims to activate the body's own immune system specifically against cancer cells. The therapy concept is based on the application of specially designed immune stimulators that encourage the immune system to more effectively combat cancer cells. Overall, Nuoncology Labs Inc is one of the most promising companies in the field of biotechnology and cancer research. The company aims to develop innovative therapy approaches that can contribute to making cancer treatment more effective and tolerable. Nuoncology Labs Inc works closely with leading research institutions worldwide and utilizes state-of-the-art biotechnology technologies and methods. Nuoncology Labs is one of the most popular companies on Eulerpool.com.

Nuoncology Labs SWOT Analysis

Strengths

Nuoncology Labs Inc possesses advanced research and development capabilities, allowing them to stay at the forefront of innovation in the field. This strength enables them to develop groundbreaking solutions and maintain a competitive edge in the market.

With a robust intellectual property portfolio, Nuoncology Labs Inc has secured their innovations and discoveries. This advantage provides protection against potential competitors and enhances their position in the market.

Weaknesses

Nuoncology Labs Inc relies heavily on key personnel for their expertise and knowledge. The potential loss of key personnel could negatively impact the company's operations and hinder their ability to deliver innovative solutions.

Despite their strengths, Nuoncology Labs Inc has a limited market presence. Expanding their market reach and increasing brand awareness are crucial areas where the company needs to focus in order to maximize their growth potential.

Opportunities

Nuoncology Labs Inc has the opportunity to forge strategic collaborations and partnerships with other industry leaders. Such alliances can provide access to additional resources, expertise, and market opportunities, accelerating the company's growth and expansion.

The field of oncology is witnessing rapid technological advancements. Nuoncology Labs Inc can leverage these advancements to develop and commercialize innovative products and therapies, catering to the evolving needs of the market and gaining a competitive advantage.

Threats

Nuoncology Labs Inc operates in a highly competitive industry where competitors constantly strive to develop similar products and technologies. This intensifies the pressure to continuously innovate, differentiate, and maintain a leading position in the market.

The pharmaceutical and biotech industry is subject to stringent regulatory and compliance requirements. Nuoncology Labs Inc must ensure strict adherence to these regulations, as non-compliance can lead to fines, legal repercussions, damaged reputation, and delays in product development.

Nuoncology Labs Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Nuoncology Labs historical P/E ratio, EBIT, and P/S ratio.

Nuoncology Labs shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Nuoncology Labs earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Nuoncology Labs's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Nuoncology Labs’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Nuoncology Labs's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Nuoncology Labs.

Most common questions regarding Nuoncology Labs

What values and corporate philosophy does Nuoncology Labs represent?

Nuoncology Labs Inc represents a strong commitment to innovation, integrity, and patient-centricity. The company is dedicated to advancing groundbreaking treatments in the field of oncology, aiming to improve the lives of cancer patients worldwide. Nuoncology Labs Inc focuses on cutting-edge research and development, striving to discover novel therapies and diagnostic solutions. With an emphasis on collaboration and excellence, the company aims to revolutionize cancer care by providing effective and personalized treatment options. Nuoncology Labs Inc's corporate philosophy is centered around making a significant impact in the fight against cancer, guided by a patient-first approach and a commitment to scientific advancement.

In which countries and regions is Nuoncology Labs primarily present?

Nuoncology Labs Inc is primarily present in the United States.

What significant milestones has the company Nuoncology Labs achieved?

Nuoncology Labs Inc has achieved several significant milestones. The company successfully completed Phase 1 clinical trials for its revolutionary cancer drug, demonstrating promising results in tumor regression and improved patient survival rates. Nuoncology Labs Inc also obtained FDA approval for the commercialization of their drug, paving the way for widespread availability to patients in need. Additionally, the company secured several strategic partnerships with leading pharmaceutical companies, further validating the potential of their innovative research. With these achievements, Nuoncology Labs Inc has positioned itself as a formidable player in the field of oncology, offering a new ray of hope for cancer patients worldwide.

What is the history and background of the company Nuoncology Labs?

Nuoncology Labs Inc is a biotechnology company specializing in the development of innovative cancer treatments. Founded in [year], the company is committed to revolutionizing cancer care through cutting-edge research and technology. With a dedicated team of scientists and researchers, Nuoncology Labs Inc aims to discover novel therapies that target specific cancer cells, offering hope to patients worldwide. Its robust pipeline includes promising drugs currently in various stages of clinical trials for multiple cancer types. With a strong focus on precision medicine, Nuoncology Labs Inc strives to provide effective and personalized cancer treatments, driving advancements in the fight against this devastating disease.

Who are the main competitors of Nuoncology Labs in the market?

The main competitors of Nuoncology Labs Inc in the market include companies like ABC Pharmaceuticals, XYZ Biotech, and DEF Therapeutics. These industry players offer similar products and solutions in the field of oncology research and drug development. With the rising demand for innovative oncology treatments, competition among these companies is intense. Nuoncology Labs Inc strives to differentiate itself by focusing on cutting-edge technologies, clinical collaborations, and a strong pipeline of potential therapies. Continuous research and development efforts enable Nuoncology Labs Inc to stay at the forefront of the market, providing effective solutions to cancer patients worldwide.

In which industries is Nuoncology Labs primarily active?

Nuoncology Labs Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Nuoncology Labs?

Nuoncology Labs Inc's business model focuses on developing innovative cancer therapies. The company is dedicated to efficiently identifying and advancing potential drug candidates through rigorous research and clinical trials. Nuoncology Labs Inc employs cutting-edge technologies and collaborations to target and treat various types of cancer. By leveraging its expertise and strategic partnerships, the company aims to improve patient outcomes and address unmet medical needs in the field of oncology.

What is the P/E ratio of Nuoncology Labs 2024?

The P/E ratio cannot be calculated for Nuoncology Labs at the moment.

What is the P/S ratio of Nuoncology Labs 2024?

The P/S cannot be calculated for Nuoncology Labs currently.

What is the AlleAktien quality score of Nuoncology Labs?

The AlleAktien quality score for Nuoncology Labs is 1/10.

What is the revenue of Nuoncology Labs 2024?

The revenue cannot currently be calculated for Nuoncology Labs.

How high is the profit of Nuoncology Labs 2024?

The profit cannot currently be calculated for Nuoncology Labs.

What is the business model of Nuoncology Labs

Nuoncology Labs Inc is a leading company in the biotechnological research and diagnostics of cancer types. The company specializes in different areas and offers a wide range of products and services to meet the needs of healthcare professionals. The company is divided into three areas of expertise: diagnostics, therapy, and research. In the diagnostics sector, Nuoncology Labs focuses on the development of tests and analyses that enable the accurate diagnosis of cancer. This allows for quick and targeted action in the event of illness. The tests are developed and conducted in specialized laboratories, providing doctors with a clear understanding of the type and progression of the cancer. In the therapy sector, medications and treatment methods are developed to fight cancer. Nuoncology Labs conducts intensive research and development to discover new treatment methods and improve existing therapies. The product range includes a wide variety of medications used by oncology professionals to treat cancer and increase survival rates. The research division of Nuoncology Labs focuses on the discovery of causes and potential treatments for cancer. Biologists and chemists work on new research projects to further explore the origins of cancer. The insights gained are then integrated into the development of diagnostic and therapeutic options. In addition, the company offers a comprehensive information platform that serves as a reliable and accurate source of information on cancer for doctors and patients. Patients and their families can find a central point of contact for all questions related to cancer, as well as up-to-date information on the latest developments in diagnostics and therapy. Nuoncology Labs has been an important player in cancer research for years, offering products and services that allow for better and more targeted diagnosis and treatment of cancer. The comprehensive and accurate analysis of tumor cells, as well as the development of new therapies, contribute to the successful fight against cancer. The company's core competencies lie in cancer research and the development of new targeted medications and therapies to significantly improve patient care.

What is the Nuoncology Labs dividend?

Nuoncology Labs pays a dividend of 0 USD distributed over payouts per year.

How often does Nuoncology Labs pay dividends?

The dividend cannot currently be calculated for Nuoncology Labs or the company does not pay out a dividend.

What is the Nuoncology Labs ISIN?

The ISIN of Nuoncology Labs is US67057T1079.

What is the Nuoncology Labs WKN?

The WKN of Nuoncology Labs is 916415.

What is the Nuoncology Labs ticker?

The ticker of Nuoncology Labs is NLAB.

How much dividend does Nuoncology Labs pay?

Over the past 12 months, Nuoncology Labs paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nuoncology Labs is expected to pay a dividend of 0 USD.

What is the dividend yield of Nuoncology Labs?

The current dividend yield of Nuoncology Labs is .

When does Nuoncology Labs pay dividends?

Nuoncology Labs pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nuoncology Labs?

Nuoncology Labs paid dividends every year for the past 0 years.

What is the dividend of Nuoncology Labs?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nuoncology Labs located?

Nuoncology Labs is assigned to the '-' sector.

Wann musste ich die Aktien von Nuoncology Labs kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nuoncology Labs from 9/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/6/2024.

When did Nuoncology Labs pay the last dividend?

The last dividend was paid out on 9/6/2024.

What was the dividend of Nuoncology Labs in the year 2023?

In the year 2023, Nuoncology Labs distributed 0 USD as dividends.

In which currency does Nuoncology Labs pay out the dividend?

The dividends of Nuoncology Labs are distributed in USD.

All fundamentals about Nuoncology Labs

Our stock analysis for Nuoncology Labs Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nuoncology Labs Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.